EUVIMEDEUVIMED entdecken
Open Access

AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans

Chantal J M van Opbergen iD, Bitha Narayanan iD, Chester B Sacramento, Katie M Stiles iD, Vartika Mishra, Esther Frenk iD, David Ricks iD, Grace Chen, Mingliang Zhang, Paul Yarabe, Jonathan Schwartz iD, Mario Delmar iD und 2 weitere

Circulation: Genomic and Precision Medicine · 2024-02 · 17 (1)

DOI: 10.1161/circgen.123.004305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2024-02. Verfasst von Chantal J M van Opbergen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY (C.J.M.v.O., G.C., M.Z., M.D., M.C.). Hauptthemen laut MEDLINE: Arrhythmogenic Right Ventricular Dysplasia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. No effective medical therapy is available to prevent or arrest the disease. We tested the hypothesis that adeno-associated virus vector–mediated delivery of the human PKP2 gene to an adult mammalian heart deficient in PKP2 can arrest disease progression and significantly prolong survival. METHODS: Experiments were performed using a PKP2-cKO (cardiac-specific, tamoxifen-activated PKP2 knockout murine model). The potential therapeutic, adeno-associated virus vector of serotype rh.74 (AAVrh.74)-PKP2a (PKP2 variant A; RP-A601) is a recombinant AAVrh.74 gene therapy viral vector encoding the human PKP2 variant A. AAVrh.74-PKP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-activated PKP2-cKO. PKP2 expression was confirmed by molecular and histopathologic analyses. Cardiac function and disease progression were monitored by survival analyses, echocardiography, and electrocardiography. RESULTS: Consistent with prior findings, loss of PKP2 expression caused 100% mortality within 50 days after tamoxifen injection. In contrast, AAVrh.74-PKP2a–mediated PKP2a expression resulted in 100% survival for >5 months (at study termination). Echocardiographic analysis revealed that AAVrh.74-PKP2a prevented right ventricle dilation, arrested left ventricle functional decline, and mitigated arrhythmia burden. Molecular and histological analyses showed AAVrh.74-PKP2a–mediated transgene mRNA and protein expression and appropriate PKP2 localization at the cardiomyocyte intercalated disc. Importantly, the therapeutic benefit was shown in mice receiving AAVrh.74-PKP2a after disease onset. CONCLUSIONS: These preclinical data demonstrate the potential for AAVrh.74-PKP2a (RP-A601) as a therapeutic for PKP2-related arrhythmogenic right ventricular cardiomyopathy in both early and more advanced stages of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arrhythmogenic Right Ventricular DysplasiaAdultHumansMiceAnimalsPlakophilinsMyocytes, CardiacArrhythmias, CardiacTamoxifenDisease ProgressionMammals

Stichwörter der Autor:innen

arrhythmogenic right ventricular cardiomyopathycardiomyopathiesdeath, suddengenetic therapyplakophilins

Substanzen

PlakophilinsTamoxifen

Autor:innen und Institutionen

  • Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY (C.J.M.v.O., G.C., M.Z., M.D., M.C.).
  • Rocket Pharmaceuticals, Inc, Cranbury, NJ (B.N., C.B.S., K.M.S., V.M., E.F., D.R., P.Y., J.S., C.D.H.).

ORCID-Profile: Chantal J M van Opbergen, Bitha Narayanan, Katie M Stiles, Esther Frenk, David Ricks, Jonathan Schwartz, Mario Delmar, Marina Cerrone

Förderung

  • NHLBI NIH HHS

Zitieren

APA

van Opbergen, C. J. M., Narayanan, B., Sacramento, C. B., Stiles, K. M., Mishra, V., Frenk, E., Ricks, D., Chen, G., Zhang, M., Yarabe, P., Schwartz, J., Delmar, M., Herzog, C. D., & Cerrone, M. (2024). AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans. Circulation: Genomic and Precision Medicine, 17(1). https://doi.org/10.1161/circgen.123.004305

Vancouver

van Opbergen CJM, Narayanan B, Sacramento CB, Stiles KM, Mishra V, Frenk E, et al. AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans. Circulation: Genomic and Precision Medicine. 2024;17(1). doi:10.1161/circgen.123.004305

BibTeX
@article{vanOpbergen2024,
  author = {van Opbergen, Chantal J M and Narayanan, Bitha and Sacramento, Chester B and Stiles, Katie M and Mishra, Vartika and Frenk, Esther and Ricks, David and Chen, Grace and Zhang, Mingliang and Yarabe, Paul and Schwartz, Jonathan and Delmar, Mario and Herzog, Chris D and Cerrone, Marina},
  title = {AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1161/circgen.123.004305}
}
Kostenlos starten →